Posters, white papers and other resources

Evidence

At Rarity Bioscience we are aiming at radically improving cancer diagnostic. We are developing a technology with the power of saving people’s lives. The technology is time efficient, high sensitive and allow optimal clinical decisions at the right time to improve patient outcome. Our assay technology is based on the groundbreaking discovery of SuperRCA (Prof. Ulf Landegren and Dr. Lei Chen) – here is the evidence.

Publications

Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays

With an innovative, super sensitive technology, so-called superRCA analyzes, any remaining cancer cells can be detected after treatment of acute myeloid leukemia (AML). The method is presented in an article in Nature Communication, this is the technology on which Rarity Bioscience is based and the article describes the application in Leukemia.

Read the article in full, in Nature Communications: “Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays”.

Molecular tools to monitor health and disease – and lucky coincidences

”Improved methods for molecular analyses are obviously central for medical research. I will describe herein our work developing tools to reveal molecular states in health and disease. I will recount how I got started in this endeavor, and how our early work characterizing genetic variation led onto high-throughput protein measurements and to techniques for imaging the distribution of proteins and their activity states in tissues. I will also describe a more recent technique to measure even exceedingly rare genetic variants in order to monitor recurrence of disease for tumor patients.”

Read the article in full, in Upsala Journal of Medical Sciences: “Molecular tools to monitor health and disease – and lucky coincidences”.

Posters

European Society for Medical Oncology

Dr. Lei Chen presented poster #629P; Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays –winning Best Poster award 2022. The scientific committee pointed out that the data provided new and valuable perspectives for monitoring of Leukemia patients.

Click on image to enlarge.

Cancer Research conference

Poster presentation by Lei Chen,PhD at the European Association for Cancer Research conference on Liquid Biopsy in Bergamo, Italy. The poster focused on the superRCA single tube assay workflow, the assay sensitivity and precision, followed by multiplex example from colorectal patients.

Click on image to enlarge.

Nordic Flow Cytometry

Lei Chen, PhD attended the Nordic Flow Cytometry meeting in Oslo where he presented this poster on the topic of Ultra-sensitive monitoring of leukemia patients using SuperRCA mutation detection assays with Flow Cytometer Readout.

Click on image to enlarge.

Whitepapers

ELC301 translational study

On behalf of the sponsor, Elicera Therapeutics, Rarity is supporting the ELC301 translational study with analysis of the vector copy number (VCN) of integrated retroviral vectors in engineered Human T-cells.

Click on image to enlarge.